MARKET

AARD

AARD

Aardvark Therapeutics
NASDAQ
10.39
-0.03
-0.29%
Opening 11:52 05/12 EDT
OPEN
10.15
PREV CLOSE
10.42
HIGH
10.84
LOW
10.15
VOLUME
5.14K
TURNOVER
--
52 WEEK HIGH
19.58
52 WEEK LOW
4.880
MARKET CAP
222.18M
P/E (TTM)
-10.7914
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AARD last week (0505-0509)?
Weekly Report · 3h ago
Weekly Report: what happened at AARD last week (0428-0502)?
Weekly Report · 05/05 12:44
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 04/29 12:07
Weekly Report: what happened at AARD last week (0421-0425)?
Weekly Report · 04/28 13:00
Weekly Report: what happened at AARD last week (0414-0418)?
Weekly Report · 04/21 12:59
Soleno Therapeutics: Navigating the Path to Profitability with Vykat XR
Barchart · 04/17 19:18
Why United Airlines Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Benzinga · 04/16 09:11
Weekly Report: what happened at AARD last week (0407-0411)?
Weekly Report · 04/14 12:41
More
About AARD
More
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).
Recently
Symbol
Price
%Change

Webull offers Aardvark Therapeutics, Inc. stock information, including NASDAQ: AARD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AARD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AARD stock methods without spending real money on the virtual paper trading platform.